|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: A meta-analysis显示文摘AIM: To determine the clinical impact of portal vein thrombosis in terms of both mortality and hepatic decompensations(variceal hemorrhage, ascites, portosystemic encephalopathy) in adult patients with cirrhosis.METHODS: We identified original articles reported through February 2015 in MEDLINE, Scopus, Science Citation Index, AMED, the Cochrane Library, and relevant examples available in the grey literature. Two independent reviewers screened all citations for inclusion criteria and extracted summary data. Random effects odds ratios were calculated to obtain aggregate estimates of effect size across included studies, with 95%CI.RESULTS: A total of 226 citations were identified and reviewed, and 3 studies with 2436 participants were included in the meta-analysis of summary effect. Patients with portal vein thrombosis had an increased risk of mortality(OR = 1.62, 95%CI: 1.11-2.36, P = 0.01). Portal vein thrombosis was associated with an increased risk of ascites(OR = 2.52, 95%CI: 1.63-3.89, P < 0.001). There was insufficient data available to determine the pooled effect on other markers of decompensation including gastroesophageal variceal bleeding or hepatic encephalopathy. CONCLUSION: Portal vein thrombosis appears to increase mortality and ascites, however, the relatively small number of included studies limits more generalizable conclusions. More trials with a direct comparison group are needed. | Jonathan G Stine Puja M Shah Scott L Cornella Sean R Rudnick Marwan S Ghabril George J Stukenborg Patrick G Northup | 2015 | World Journal of Hepatology2015，7，27： | 42 |
| 2 | Current oncologic applications of radiofrequency ablation therapies显示文摘Radiofrequency ablation (RFA) uses high frequency alternating current to heat a volume of tissue around a needle electrode to induce focal coagulative necrosis with minimal injury to surrounding tissues. RFA can be performed via an open, laparoscopic, or image guided percutaneous approach and be performed under general or local anesthesia. Advances in delivery mechanisms, electrode designs, and higher power generators have increased the maximum volume that can be ablated, while maximizing oncological outcomes. In general, RFA is used to control local tumor growth, prevent recurrence, palliate symptoms, and improve survival in a subset of patients that are not candidates for surgical resection. It's equivalence to surgical resection has yet to be proven in large randomized control trials. Currently, the use of RFA has been well described as a primary or adjuvant treatment modality of limited but unresectable hepatocellular carcinoma, liver metastasis, especially colorectal cancer metastases, primary lung tumors, renal cell carcinoma, boney metastasis and osteoid osteomas. The role of RFA in the primary treatment of early stage breast cancer is still evolving. This review will discuss the general features of RFA and outline its role in commonly encountered solid tumors. | Dhruvil R Shah Sari Green Angelina Elliot John P McGahan Vijay P Khatri | 2013 | World Journal of Gastrointestinal Oncology2013，5，4： | 33 |
| 3 | Bone mineral density and disorders of mineral metabolism in chronic liver disease显示文摘AIM:To estimate the prevalence and identify the risk factors for metabolic bone disease in patients with cirrhosis.METHODS:The study was performed on 72 Indian patients with cirrhosis(63 male, 9 female;aged < 50 years).Etiology of cirrhosis was alcoholism(n = 37), hepatitis B(n = 25) and hepatitis C(n = 10).Twenty-three patients belonged to Child class A, while 39 were in class B and 10 in class C.Secondary causes for metabolic bone disease and osteoporosis were ruled out.Sunlight exposure, physical activity and dietary constituents were calculated.Complete metabolic profiles were derived, and bone mineral density(BMD) was measured using dual energy X ray absorptiometry.Low BMD was defined as a Z score below-2.RESULTS:Low BMD was found in 68% of patients.Lumbar spine was the most frequently and severely affected site.Risk factors for low BMD included low physical activity, decreased sunlight exposure, and low lean body mass.Calcium intake was adequate, with unfavorable calcium:protein ratio and calcium:phosphorus ratio.Vitamin D deficiency was highly prevalent(92%).There was a high incidence of hypogonadism(41%).Serum estradiol level was elevated significantly in patients with normal BMD.Insulin-like growth factor(IGF) 1 and IGF binding protein 3 levels were below the age-related normal range in both groups.IGF-1 was signiflcantly lower in patients with low BMD.Serum osteocalcin level was low(68%) and urinary deoxypyridinoline to creatinine ratio was high(79%), which demonstrated low bone formation with high resorption.CONCLUSION:Patients with cirrhosis have low BMD.Contributory factors are reduced physical activity, low lean body mass, vitamin D def iciency and hypogonadism and low IGF-1 level. | Joe George Hosahithlu K Ganesh Shrikrishna Acharya Tushar R Bandgar Vyankatesh Shivane Anjana Karvat Shobna J Bhatia Samir Shah Padmavathy S Menon Nalini Shah | 2009 | World Journal of Gastroenterology2009，15，28： | 15 |
| 4 | MicroRNAs in pathogenesis of breast cancer:Implications in diagnosis and treatment显示文摘MicroR NAs(miR NAs) are small non-coding RNAs generated by a two-step complex process and are post transcriptional negative regulators of their target m RNAs. Dysregulation of many of these miR NAs has been associated with tumorigenesis in various cancers including breast cancer. Aberrantly high expression of specific mi RNAs in breast cancer cells is demonstrated to be linked with inhibition of tumor suppressor genes and promote tumorigenesis. They are classified as oncogenic miR NAs. However, the tumor suppressor miR NAs are downregulated in breast cancer cells, since their major targets are oncogenic m RNAs. Understanding mechanism of action of specific miR NAs in breast cancer cells can be utilized to develop newer anti-cancer therapies. Recently, newer techniques are also developed to detect abundance of specific miR NA in the blood plasma samples and can be used in early diagnosis or prognosis in breast cancer. In this review article, we have discussed several mi RNAs dysregulated in breast cancer and their therapeutic potential. | Nirav R Shah Hexin Chen | 2014 | World Journal of Clinical Oncology2014，5，2： | 8 |
| 5 | Screening pre-bariatric surgery patients for esophageal disease with esophageal capsule endoscopy显示文摘AIM:To determine if esophageal capsule endoscopy(ECE)is an adequate diagnostic alternative to esophagogastroduodenoscopy(EGD)in pre-bariatric surgery patients.METHODS:We conducted a prospective pilot study to assess the diagnostic accuracy of ECE(PillCam ESO2,Given Imaging)vs conventional EGD in pre-bariatric surgery patients.Patients who were scheduled for bariatric surgery and referred for pre-operative EGD were prospectively enrolled.All patients underwent ECE followed by standard EGD.Two experienced gastroenterologists blinded to the patient’s history and the findings of the EGD reviewed the ECE and documented their findings.The gold standard was the findings on EGD.RESULTS:Ten patients with an average body mass index of 50 kg/m2were enrolled and completed the study.ECE identified 11 of 14(79%)positive esophageal/gastroesophageal junction(GEJ)findings and 14of 17(82%)combined esophageal and gastric findings identified on EGD.Fisher’s exact test was used to compare the findings and no significant difference was found between ECE and EGD(P=0.64 for esophageal/GEJ and P=0.66 for combined esophageal and gastric findings respectively).Of the positive esophageal/GEJ findings,ECE failed to identify the following:hiatal hernia in two patients,mild esophagitis in two patients,and mild Schatzki ring in two patients.ECE was able to identify the entire esophagus in 100%,gastric cardia in0%,gastric body in 100%,gastric antrum in 70%,pylorus in 60%,and duodenum in 0%.CONCLUSION:There were no significant differences in the likelihood of identifying a positive finding using ECE compared with EGD in preoperative evaluation of bariatric patients. | Ashish Shah Erica Boettcher Marianne Fahmy Thomas Savides Santiago Horgan Garth R Jacobsen Bryan J Sandler Michael Sedrak Denise Kalmaz | 2013 | World Journal of Gastroenterology2013，19，37： | 7 |
| 6 | 终末期肾病患者大血管和微血管内皮功能障碍与亚临床心功能不全的关系显示文摘终末期肾病(end-stagerenaldisease,ESRD)患者的心脏衰竭和心血管病死亡率较高,而我们对此缺乏深入透彻的了解,是否存在可变因素导致了这些高危患者发生心功能不全。为了评估血管内皮功能能否作为ESRD患者潜在的心功能不全的可变因素,研究人员应用横断面研究在一个控制良好的ESRD队列中,分析大血管和微血管功能障碍与左、右心功能不全的相关性。 | 刘莉 叶鹏 Dubin RF Guajardo I Ayer A Mills C Donovan C Beussink L Scherzer R Ganz P Shah SJ | 2016 | 中华高血压杂志2016，24，9： | 5 |
| 7 | Perspectives on the prevention and treatment of infection for orthopedic tissue engineering applications显示文摘The emergence of orthopedic tissue engineering devices as viable clinical solutions demands that the field address significant clinical complications associated with the implantation of foreign materials in the body,especially infection.While tissue engineering has focused on the development of methods to regenerate and repair,until recently there has been a relative dearth of literature regarding the intersection of tissue engineering and infection.In particular,local delivery of antimicrobials has long been of clinical interest,but only recently has that been translated into the realm of tissue engineering.In this perspective,we briefly review major modes of local delivery for infection prevention and treatment and discuss possible strategies for preventing implant-associated infections. | SHAH Sarita R KASPER F Kurtis MIKOS Antonios G | 2013 | Chinese Science Bulletin2013，58，35： | 4 |
| 8 | Response of blood pressure after percutaneous transluminal renal artery angioplasty and stenting显示文摘AIM: To evaluate the short and intermediate term out-come of percutaneous transluminal renal artery angioplasty (PTRA) and stenting particularly on blood pressure (BP) control and renal function and to evaluate predictors of poor BP response after successful PTRA and stenting. METHODS: We conducted a prospective analysis of all patients who underwent PTRA and stenting in our institute between August 2010 to September 2012. A total number of 86 patients were underwent PTRA and renal stenting. Selective angiography was done to confirm at least 70% angiographic stenosis. The predilatation done except few cases with critical stenosis, direct stenting was done in the rest of cases. All patients received aspirin 325 mg orally, and clopidogrel 300 mg orally within 24 h before the procedure. Heparin was used as the procedural anticoagulant agent. Optimal results with TIMI-Ⅲ flow obtained in all cases. Following stent placement, aspirin 150 mg orally once daily was continued for a minimum of 12 mo and clopidogrel 75 mg orally once daily for at least 4 wk. The clinical, radiological, electrocardiography, echocardiography and treatment data of all patients were recorded. The BP measurement, serum creatinine and glomerular filtration rate (GFR) were recorded before the procedure and 1 and 6 mo after PTRA. RESULTS: A total of 86 patients were included in the study. The mean age of study population was 55.87±11.85 years old and 67 (77.9%) of patients were male. There was a significant reduction in both systolic and diastolic BP at 1 mo after the procedure: 170.15±20.10 mmHg vs 146.60±17.32 mmHg and 98.38±10.55 mmHg vs 89.88±9.22 mmHg respectively (P=0.0000). The reduction in BP was constant throughout the follow-up period and was evident 6 mo after the procedure: 144.23±18.19 and 88.26±9.79 mmHg respectively (P=0.0000). However, no improvement in renal function was observed at any time during the follow-up period. After multivariate analysis, we found male sex, low GFR (<60 mL/min) and higher baseline mean BP as a poor predictors of successful outcome on BP response after PTRA and stenting. CONCLUSION: The PTRA and stenting can be considered as an effective therapeutic intervention for improving BP control with minimal effect on renal function. The male sex, higher baseline BP and low GFR are associated with poor BP response after successful PTRA and stenting. | Jayesh S Prajapati Sharad R Jain Hasit Joshi Shaurin Shah Kamal Sharma Sibasis Sahoo Kapil Virparia Ashok Thakkar | 2013 | World Journal of Cardiology2013，5，7： | 3 |
| 9 | 接受他汀治疗患者新发糖尿病风险:人群为基础的研究显示文摘目的 研究接受HMG-CoA还原酶抑制剂(他汀类药物)治疗的患者的新发糖尿病风险。设计 人群为基础的队列研究,以时间事件分析的方法评估各种他汀类药物应用和新发糖尿病风险的相关性分析。计算危害比(hazard ratios,HR)来确定他汀的种类及剂量与新发糖尿病的关系。 | Aleesa A Caner Tara Gomes Ximena Camacho David N Juurlink Baiju R Shah Muhammad M Mamdani 张秀珍(译) 骆斯慧(译) 翁建平(校) | 2013 | 英国医学杂志中文版2013，16，5： | 2 |
| 10 | Combination drug regimens for metastatic clear cell renal cell carcinoma显示文摘Renal cell carcinomas(RCC)make up about 90%of kidney cancers,of which 80%are of the clear cell subtype.About 20%of patients are already metastatic at the time of diagnosis.Initial treatment is often cytoreductive nephrectomy,but systemic therapy is required for advanced RCC.Single agent targeted therapies are moderately toxic and only somewhat effective,leading to development of immunotherapies and combination therapies.This review identifies limitations of monotherapies for metastatic renal cell carcinoma,discusses recent advances in combination therapies,and highlights therapeutic options under development.The goal behind combining various modalities of systemic therapy is to potentiate a synergistic antitumor effect.However,combining targeted therapies may cause increased toxicity.The initial attempts to create therapeutic combinations based on inhibition of the vascular endothelial growth factor or mammalian target of rapamycin pathways were largely unsuccessful in achieving a profile of increased synergy without increased toxicity.To date,five combination therapies have been approved by the U.S.Food and Drug Administration,with the most recently approved therapies being a combination of checkpoint inhibition plus targeted therapy.Several other combination therapies are under development,including some in the phase 3 stage.The new wave of combination therapies for metastatic RCC has the potential to increase response rates and improve survival outcomes while maintaining tolerable side effect profiles. | Viraj V Khetani Daniella E Portal Mansi R Shah Tina Mayer Eric A Singer | 2020 | World Journal of Clinical Oncology2020，11，8： | 2 |
| 11 | Kidney exchange transplantation current status, an update and future perspectives显示文摘Kidney exchange transplantation is well established modality to increase living donor kidney transplantation. Reasons for joining kidney exchange programs are ABO blood group incompatibility, immunological inco-mpatibility(positive cross match or donor specific antibody), human leukocyte antigen(HLA) incompa-tibility(poor HLA matching), chronological incompa-tibility and financial incompatibility. Kidney exchange transplantation has evolved from the traditional si-multaneous anonymous 2-way kidney exchange to more complex ways such as 3-way exchange, 4-way exchange, n -way exchange,compatible pair, non-simult-aneous kidney exchange,non-simultaneous extended altruistic donor, never ending altruistic donor, kidney exchange combined with desensitization, kidney ex-change combined with ABO incompatible kidney tr-ansplantation, acceptable mismatch transplant, use of A2 donor to O patients, living donor-deceased donor list exchange, domino chain, non-anonymous kidney exchange, single center, multicenter, regional, National, International and Global kidney exchange. Here we discuss recent advances in kidney exchanges such as International kidney exchange transplantation in a gl-obal environment, three categories of advanced dona-tion program, deceased donors as a source of chain initiating kidneys, donor renege myth or reality, pros and cons of anonymity in developed world and(non-) anonymity in developing world, pros and cons of donor travel vs kidney transport, algorithm for management of incompatible donor-recipient pairs and pros and cons of Global kidney exchange. The participating transplant teams and donor-recipient pairs should make the decision by consensus about kidney donor travel vskidney transport and anonymity vs non-anonymity in allocation as per local resources and logistics. Future of organ transplantation in resource-limited setting will be liver vs kidney exchange, a legitimate hope or utopia? | Vivek B Kute Narayan Prasad Pankaj R Shah Pranjal R Modi | 2018 | World Journal of Transplantation2018，8，3： | 2 |
| 12 | 相对于男性,女性进行冠状动脉造影产生的额外的心血管病风险与严重受损的冠状动脉血流储备,而非阻塞性疾病相关显示文摘与男性相比,女性的心血管病死亡率更高,但是阻塞性冠状动脉疾病(coronary artery disease,CAD)在女性中不太普遍。冠状动脉血流储备(coronary flow reserve,CFR)是大、小血管CAD和心肌缺血的综合测量指标,可识别出具有心血管病死亡风险的患者,但其在临床实践中不是常规测量的指标。该研究试图调查性别、CFR和血管造影CAD严重程度对不良心血管事件的影响。 | 刘莉 叶鹏 Taqueti VR Shaw LJ Cook NR Murthy VL Shah NR Foster CR Hainer J Blankstein R Dorbala S Di Carli MF | 2016 | 中华高血压杂志2016，24，11： | 2 |
| 13 | Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study显示文摘 | Nauck Michael Frid Anders Hermansen Kjeld Shah Nalini S Tankova Tsvetalina Mitha Ismail H Zdravkovic Milan Düring Maria Matthews David R | 2009 | Diabetes Care2009，，： | 2 |
| 14 | Ibuprofen for the treatment of patent ductus arteriosus in preterm and / or low birth weight infants 显示文摘 | Ohlsson A Walia R Shah S | 2005 | Cochrane Database Syst Rev2005，19，00： | 1 |
| 15 | The adequacy of laboratory moniloring in patients treated with spironolactone for congestive heart failure显示文摘 | Shah KB Rao K Sawyer R | 2005 | J Am Coll Cardiol2005，46，5： | 1 |
| 16 | CT and MRI findings of intracranial lymphoma显示文摘 | Slone HW Blake JJ Shah R | 2005 | Am J Roentgenol2005，184，5： | 1 |
| 17 | Comparison of adjustable-and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients显示文摘 | William W Busse Shailen R Shah Laura Somerville | 2008 | American Academy of Allergy2008，121，6： | 1 |
| 18 | Comparison between barium and strontium-glass composites for sealing SOFCs 显示文摘 | BROCHU M GAUNTT B D SHAH R | 2006 | J Eur Ceram Soc2006，26，： | 1 |
| 19 | Esmolol for the potentiation of nitroprusside-induced hypotension: impact on the cardiovascular adrenergic and renin-angiotensin system in man显示文摘 | EDMONDSON R DEL VALLE O SHAH N | 1989 | Anesth Analg1989，69，2： | 1 |
| 20 | Principles for Measurement of Chemical Expo- sure based on Recognition - Driven Anchoring Transitions in Liquid Crystals 显示文摘 | Shah R R Abbott N L | 2001 | Science2001，293，： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员